# Genelux (GNLX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/GNLX
## Company Profile
- Ticker: GNLX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, Oncology
## Stock Data
- Close: 2.7 USD
- Market cap: 132279227.2 USD
- Last updated: 2026-08-12
## Business Overview
### Oncolytic Immunotherapy
Genelux develops replication-competent oncolytic viruses designed to destroy tumor cells and stimulate systemic antitumor immunity. Its platform is being studied through regional and systemic administration approaches.
### Olvi-Vec
Olvi-Vec is the company's lead vaccinia-virus candidate. The registrational OnPrime/GOG-3076 study evaluates intraperitoneal Olvi-Vec followed by chemotherapy and bevacizumab in platinum-resistant or refractory ovarian cancer.
### Systemic Lung-Cancer Programs
Genelux is also advancing systemic Olvi-Vec studies in lung cancer, seeking to extend the platform beyond tumors accessible through localized administration.
## Why The Stock Is Moving

The latest monitored company update is “Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Topline data from the Phase 3 OnPrime/GOG-3076 study of Olvi-Vec in ovarian cancer in the second half of 2026.
- Dose-escalation updates from systemic Olvi-Vec studies in lung cancer during 2026.

## Recent News
- 2026-08-13 20:20 EST — [Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates](https://biopharmsignal.com/news/GNLX/genelux-corporation-reports-second-quarter-financial-results-and-provides-busine-43a38a1c) — Source: Genelux
- 2026-06-30 12:00 EST — [Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer](https://biopharmsignal.com/news/GNLX/genelux-announces-publication-of-translational-analysis-supporting-immune-activa-f94dc658) — Source: Genelux
- 2026-05-07 20:15 EST — [Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates](https://biopharmsignal.com/news/GNLX/genelux-corporation-reports-first-quarter-financial-results-and-provides-busines-4da315c4) — Source: Genelux
- 2026-03-19 20:15 EST — [Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/GNLX/genelux-corporation-reports-fourth-quarter-and-full-year-2025-financial-results--c85e79a0) — Source: Genelux
- 2026-02-18 13:00 EST — [Genelux Corporation to Participate in Upcoming Conferences](https://biopharmsignal.com/news/GNLX/genelux-corporation-to-participate-in-upcoming-conferences-2aef90ae) — Source: Genelux